Management of graves disease a review

JAMA - Journal of the American Medical Association

Volumn 314, Issue 23, 2015, Pages 2544-2554

  Burch, Henry B ^a,b   Cooper, David S ^c  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTITHYROID AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBIMAZOLE; HEMOPOIETIC GROWTH FACTOR; LEVOTHYROXINE; METOPROLOL; POTASSIUM IODIDE; PROPYLTHIOURACIL; RADIOACTIVE IODINE; THIAMAZOLE; THIONAMIDE;

AGE DISTRIBUTION; AGRANULOCYTOSIS; ANCA ASSOCIATED VASCULITIS; ARTHRALGIA; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DIGITAL CLUBBING; ENDOCRINE OPHTHALMOPATHY; GASTROINTESTINAL SYMPTOM; GEOGRAPHIC DISTRIBUTION; GRAVES DISEASE; HORMONE SUBSTITUTION; HUMAN; HYPERTHYROIDISM; HYPOPARATHYROIDISM; LIVER INJURY; LIVER TOXICITY; MEDICAL HISTORY; META ANALYSIS (TOPIC); NECK PAIN; PATHOGENESIS; PATIENT PREFERENCE; POSTOPERATIVE COMPLICATION; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SEX DIFFERENCE; SKIN DISEASE; SYMPTOMATOLOGY; SYSTEMATIC REVIEW (TOPIC); THYROID FUNCTION TEST; THYROIDECTOMY; THYROIDITIS; THYROTOXICOSIS; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; VOCAL CORD PARALYSIS; ADULT; DISEASE MANAGEMENT; FEMALE; MALE; PREGNANCY COMPLICATIONS; PROCEDURES;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ANTITHYROID AGENTS; DISEASE MANAGEMENT; FEMALE; GRAVES DISEASE; HUMANS; IODINE RADIOISOTOPES; MALE; POTASSIUM IODIDE; PREGNANCY; PREGNANCY COMPLICATIONS; THYROIDECTOMY;

EID: 84950162371     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.16535     Document Type: Review

References (106)

1. Nystr HF, Jansson S, Berg G. Incidence rate and clinical features of hyperthyroidism in a long-Term iodine sufficient area of Sweden (Gothenburg) 2003-2005. Clin Endocrinol (Oxf). 2013;78(5):768-776.
2. McLeod DS, Caturegli P, Cooper DS, Matos PG, Hutfless S. Variation in rates of autoimmune thyroid disease by race/ethnicity in US military personnel. JAMA. 2014;311(15):1563-1565.
3. Burch HB. Overview of the clinical manifestations of thyrotoxicosis. In: Braverman LE, ed.Werner & Ingbar's The Thyroid. 10th ed. Philadelphia, PA: LippincottWilliams &Wilkins; 2013:434-440.
4. Boelaert K, Torlinska B, Holder RL, Franklyn JA. Older subjects with hyperthyroidism present with a paucity of symptoms and signs: A large cross-sectional study. J Clin Endocrinol Metab. 2010;95(6):2715-2726.
5. Frost L, Vestergaard P, Mosekilde L. Hyperthyroidism and risk of atrial fibrillation or flutter: A population-based study. Arch Intern Med. 2004;164(15):1675-1678.
6. Karga H, Papapetrou PD, Korakovouni A, Papandroulaki F, Polymeris A, Pampouras G. Bone mineral density in hyperthyroidism. Clin Endocrinol (Oxf). 2004;61(4):466-472.
7. Bahn Chair RS, Burch HB, Cooper DS, et al; American Thyroid Association; American Association of Clinical Endocrinologists. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011;21(6):593-646.
8. Ide A, Amino N, Kang S, et al. Differentiation of postpartum Graves thyrotoxicosis from postpartum destructive thyrotoxicosis using antithyrotropin receptor antibodies and thyroid blood flow. Thyroid. 2014;24(6):1027-1031.
9. Bahn RS. Autoimmunity and Graves disease. Clin Pharmacol Ther. 2012;91(4):577-579.
10. Matos-Santos A, Nobre EL, Costa JG, et al. Relationship between the number and impact of stressful life events and the onset of Graves disease and toxic nodular goitre. Clin Endocrinol (Oxf). 2001;55(1):15-19.
11. Hancock SL, Cox RS, McDougall IR. Thyroid diseases after treatment of Hodgkins disease. N Engl J Med. 1991;325(9):599-605.
12. Laurberg P,Wallin G, Tallstedt L, Abraham-NordlingM, Lundell G, Tring O. TSH-receptor autoimmunity in Graves disease after therapy with anti-Thyroid drugs, surgery, or radioiodine: A 5-year prospective randomized study. Eur J Endocrinol. 2008;158(1):69-75.
13. Laurberg P, Buchholtz Hansen PE, Iversen E, Eskjaer Jensen S,Weeke J. Goitre size and outcome of medical treatment of Graves disease. Acta Endocrinol (Copenh). 1986;111(1):39-43.
14. Laurberg P. Remission of Graves disease during anti-Thyroid drug therapy: Time to reconsider the mechanism? Eur J Endocrinol. 2006;155(6):783-786.
15. Uchida T, Goto H, Kasai T, et al. Therapeutic effectiveness of potassium iodine in drug-nae patients with Graves disease: A single-center experience. Endocrine. 2014;47(2):506-511.
16. Burch HB, Solomon BL, Cooper DS, Ferguson P, Walpert N, Howard R. The effect of antithyroid drug pretreatment on acute changes in thyroid hormone levels after (131)I ablation for Graves disease. J Clin Endocrinol Metab. 2001;86(7):3016-3021.
17. Luewan S, Chakkabut P, Tongsong T. Outcomes of pregnancy complicated with hyperthyroidism: A cohort study. Arch Gynecol Obstet. 2011;283(2): 243-247.
18. Cooper DS. Antithyroid drugs in the management of patients with Graves disease: An evidence-based approach to therapeutic controversies. J Clin Endocrinol Metab. 2003;88(8): 3474-3481.
19. Sundaresh V, Brito JP,Wang Z, et al. Comparative effectiveness of therapies for Graves hyperthyroidism: A systematic review and network meta-Analysis. J Clin Endocrinol Metab. 2013;98(9): 3671-3677.
20. Vitti P, Rago T, Chiovato L, et al. Clinical features of patients with Graves disease undergoing remission after antithyroid drug treatment. Thyroid. 1997;7(3):369-375.
21. Trsk F, Tallstedt L, Abraham-NordlingM, et al; Thyroid Study Group of TT 96. Thyroid-Associated ophthalmopathy after treatment for Graves hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab. 2009;94(10): 3700-3707.
22. Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA, Udelsman R. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg. 1998;228 (3):320-330.
23. Burch HB, Burman KD, Cooper DSA. A 2011 survey of clinical practice patterns in the management of Graves disease. J Clin Endocrinol Metab. 2012;97(12):4549-4558.
24. Bartalena L, Burch HB, Burman KD, Kahaly GJA. A 2013 European survey of clinical practice patterns in the management of Graves disease [published online December 8, 2014]. Clin Endocrinol (Oxf). 2014. doi:10.1111/cen.12688.
25. Abraham-NordlingM, Tring O, Hamberger B, et al. Graves disease: A long-Term quality-of-life follow up of patients randomized to treatment with antithyroid drugs, radioiodine, or surgery. Thyroid. 2005;15(11):1279-1286.
26. Patel NN, Abraham P, Buscombe J, Vanderpump MP. The cost effectiveness of treatment modalities for thyrotoxicosis in a U.K. center. Thyroid. 2006;16(6):593-598.
27. In H, Pearce EN,Wong AK, Burgess JF, McAneny DB, Rosen JE. Treatment options for Graves disease: A cost-effectiveness analysis. J Am Coll Surg. 2009;209(2):170-179.
28. Neumann S, Nir EA, Eliseeva E, et al. A selective TSH receptor antagonist inhibits stimulation of thyroid function in femalemice. Endocrinology. 2014;155(1):310-314.
29. Perrild H, Hansen JM, Skovsted L, Christensen LK. Different effects of propranolol, alprenolol, sotalol, atenolol and metoprolol on serum T3 and serum rT3 in hyperthyroidism. Clin Endocrinol (Oxf). 1983;18(2):139-142.
30. Cooper DS, Daniels GH, Ladenson PW, Ridgway EC. Hyperthyroxinemia in patients treated with high-dose propranolol. Am J Med. 1982;73(6): 867-871.
31. Geffner DL, Hershman JM. Beta-Adrenergic blockade for the treatment of hyperthyroidism. Am J Med. 1992;93(1):61-68.
32. Roti E, Montermini M, Roti S, et al. The effect of diltiazem, a calcium channel-blocking drug, on cardiac rate and rhythm in hyperthyroid patients. Arch Intern Med. 1988;148(9):1919-1921.
33. Warnock AL, Cooper DS, Burch HB. Life threatening thyrotoxicosis: Thyroid storm and adverse effects of antithyroid drugs [published online June 11, 2014]. Endocrine and Metabolic Medical Emergencies. 2014. doi:10.1210/EME .9781936704811.ch11.
34. Cooper DS. Antithyroid drugs. N Engl J Med. 2005;352(9):905-917.
35. Emiliano AB, Governale L, Parks M, Cooper DS. Shifts in propylthiouracil and methimazole prescribing practices: Antithyroid drug use in the United States from 1991 to 2008. J Clin Endocrinol Metab. 2010;95(5):2227-2233.
36. McCruden DC, Hilditch TE, Connell JM, McLellan AR, Robertson J, Alexander WD. Duration of antithyroid action ofmethimazole estimated with an intravenous perchlorate discharge test. Clin Endocrinol (Oxf). 1987;26(1):33-39.
37. Nakamura H, Noh JY, Itoh K, Fukata S,Miyauchi A, Hamada N. Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves disease. J Clin Endocrinol Metab. 2007;92(6):2157-2162.
38. Chen JJ, Ladenson PW. Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves disease. J Clin Endocrinol Metab. 1986;63(1):102-106.
39. Kashiwai T, Hidaka Y, Takano T, et al. Practical treatment with minimum maintenance dose of anti-Thyroid drugs for prediction of remission in Graves disease. Endocr J. 2003;50(1):45-49.
40. Young ET, Steel NR, Taylor JJ, et al. Prediction of remission after antithyroid drug treatment in Graves disease. Q J Med. 1988;66(250):175-189.
41. Carella C, Mazziotti G, Sorvillo F, et al. Serum thyrotropin receptor antibodies concentrations in patients with Graves disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period. Thyroid. 2006;16(3):295-302.
42. Liu X, QiangW, Liu X, et al. A second course of antithyroid drug therapy for recurrent Graves disease: An experience in endocrine practice. Eur J Endocrinol. 2015;172(3):321-326.
43. Howard JE. Treatment of thyrotoxicosis. JAMA. 1967;202(8):706-709.
44. Azizi F, Ataie L, Hedayati M, Mehrabi Y, Sheikholeslami F. Effect of long-Term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine. Eur J Endocrinol. 2005;152(5):695-701.
45. Otsuka F, Noh JY, Chino T, et al. Hepatotoxicity and cutaneous reactions after antithyroid drug administration. Clin Endocrinol (Oxf). 2012;77(2): 310-315.
46. Nakamura H,Miyauchi A, Miyawaki N, Imagawa J. Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan. J Clin Endocrinol Metab. 2013;98(12):4776-4783.
47. Gao Y, Chen M, Ye H, Yu F, Guo XH, Zhao MH. Long-Term outcomes of patients with propylthiouracil-induced anti-neutrophil cytoplasmic auto-Antibody-Associated vasculitis. Rheumatology (Oxford). 2008;47(10):1515-1520.
48. Takata K, Kubota S, Fukata S, et al. Methimazole-induced agranulocytosis in patients with Graves disease is more frequent with an initial dose of 30mg daily than with 15mg daily. Thyroid. 2009;19(6):559-563.
49. Kobayashi S, Noh JY, Mukasa K, et al. Characteristics of agranulocytosis as an adverse effect of antithyroid drugs in the second or later course of treatment. Thyroid. 2014;24(5):796-801.
50. Sheng WH, Hung CC, Chen YC, et al. Antithyroid-drug-induced agranulocytosis complicated by life-Threatening infections. QJM. 1999;92(8):455-461.
51. Robinson J, Richardson M, Hickey J, et al. Patient knowledge of antithyroid drug-induced agranulocytosis. Eur Thyroid J. 2014;3(4):245-251.
52. Andersohn F, Konzen C, Garbe E. Systematic review: Agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med. 2007; 146(9):657-665.
53. Andr E, Zimmer J, Mecili M,Weitten T, Alt M, Maloisel F. Clinical presentation and management of drug-induced agranulocytosis. Expert Rev Hematol. 2011;4(2):143-151.
54. Tajiri J, Noguchi S, Murakami T, Murakami N. Antithyroid drug-induced agranulocytosis: The usefulness of routine white blood cell count monitoring. Arch Intern Med. 1990;150(3):621-624.
55. Woeber KA.Methimazole-induced hepatotoxicity. Endocr Pract. 2002;8(3):222-224.
56. Bahn RS, Burch HB, Cooper DS, et al. The role of propylthiouracil in the management of Graves disease in adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid. 2009;19(7):673-674.
57. WangMT, LeeWJ, Huang TY, Chu CL, Hsieh CH. Antithyroid drug-related hepatotoxicity in hyperthyroidism patients: A population-based cohort study. Br J Clin Pharmacol. 2014;78(3):619-629.
58. Yang J, Li LF, Xu Q, et al. Analysis of 90 cases of antithyroid drug-induced severe hepatotoxicity over 13 years in China. Thyroid. 2015;25(3):278-283.
59. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med. 2006;354(7):731-739.
60. Harper L, Chin L, Daykin J, et al. Propylthiouracil and carbimazole associated-Antineutrophil cytoplasmic antibodies (ANCA) in patients with Graves disease. Clin Endocrinol (Oxf). 2004;60(6):671-675.
61. Gao Y, Zhao MH. Review article: drug-induced anti-neutrophil cytoplasmic antibody-Associated vasculitis. Nephrology (Carlton). 2009;14(1):33-41.
62. Burch HB,Wartofsky L. Life-Threatening thyrotoxicosis: Thyroid storm. Endocrinol Metab Clin North Am. 1993;22(2):263-277.
63. McDermottMT, Kidd GS, Dodson LE Jr, Hofeldt FD. Radioiodine-induced thyroid storm: case report and literature review. Am J Med. 1983;75(2):353-359.
64. Ross DS. Radioiodine therapy for hyperthyroidism.NEngl J Med. 2011;364(6):542-550.
65. Braga M,Walpert N, Burch HB, Solomon BL, Cooper DS. The effect of methimazole on cure rates after radioiodine treatment for Graves hyperthyroidism: A randomized clinical trial. Thyroid. 2002;12(2):135-139.
66. Alexander EK, Larsen PR. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves disease. J Clin Endocrinol Metab. 2002;87(3):1073-1077.
67. Burch HB, Solomon BL,Wartofsky L, Burman KD. Discontinuing antithyroid drug therapy before ablation with radioiodine in Graves disease. Ann Intern Med. 1994;121(8):553-559.
68. Andrade VA, Gross JL, Maia AL. Effect of methimazole pretreatment on serum thyroid hormone levels after radioactive treatment in Graves hyperthyroidism. J Clin Endocrinol Metab. 1999;84(11):4012-4016.
69. Kubota S, Ohye H, Yano G, et al. Two-day thionamide withdrawal prior to radioiodine uptake sufficiently increases uptake and does not exacerbate hyperthyroidism compared to 7-day withdrawal in Graves disease. Endocr J. 2006;53 (5):603-607.
70. WalterMA, Christ-CrainM, Schindler C, Mller-Brand J, Mller B. Outcome of radioiodine therapy without, on or 3 days off carbimazole: A prospective interventional three-group comparison. Eur J Nucl Med Mol Imaging. 2006;33 (6):730-737.
71. WalterMA, BrielM, Christ-CrainM, et al. Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-Analysis of randomised controlled trials. BMJ. 2007;334(7592):514.
72. Sisson JC, Freitas J, McDougall IR, et al; American Thyroid Association Taskforce On Radioiodine Safety. Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I : practice recommendations of the American Thyroid Association. Thyroid. 2011;21 (4):335-346.
73. Tallstedt L, Lundell G, Tring O, et al; The Thyroid Study Group. Occurrence of ophthalmopathy after treatment for Graves hyperthyroidism. N Engl J Med. 1992;326(26):1733-1738.
74. Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism and the course of Graves ophthalmopathy. N Engl J Med. 1998;338(2):73-78.
75. Acharya SH, Avenell A, Philip S, Burr J, Bevan JS, Abraham P. Radioiodine therapy (RAI) for Graves disease (GD) and the effect on ophthalmopathy: A systematic review. Clin Endocrinol (Oxf). 2008;69(6):943-950.
76. Prummel MF,Wiersinga WM. Smoking and risk of Graves disease. JAMA. 1993;269(4):479-482.
77. Shiber S, Stiebel-Kalish H, Shimon I, Grossman A, Robenshtok E. Glucocorticoid regimens for prevention of Graves ophthalmopathy progression following radioiodine treatment: systematic review and meta-Analysis. Thyroid. 2014;24(10):1515-1523.
78. Ron E, Doody MM, Becker DV, et al; Cooperative Thyrotoxicosis Therapy Follow-up Study Group. Cancer mortality following treatment for adult hyperthyroidism. JAMA. 1998;280(4):347-355.
79. Dale J, Daykin J, Holder R, Sheppard MC, Franklyn JA.Weight gain following treatment of hyperthyroidism. Clin Endocrinol (Oxf). 2001;55(2): 233-239.
80. Elfenbein DM, Schneider DF, Havlena J, Chen H, Sippel RS. Clinical and socioeconomic factors influence treatment decisions in Graves disease. Ann Surg Oncol. 2015;22(4):1196-1199.
81. Jin J, Sandoval V, Lawless ME, Sehgal AR, McHenry CR. Disparity in the management of Graves disease observed at an urban county hospital: A decade-long experience. Am J Surg. 2012;204(2):199-202.
82. Feroci F, RettoriM, Borrelli A, et al. A systematic review and meta-Analysis of total thyroidectomy versus bilateral subtotal thyroidectomy for Graves disease. Surgery. 2014; 155(3):529-540.
83. Erbil Y, Ozluk Y, Giriş M, et al. Effect of lugol solution on thyroid gland blood flow and microvessel density in the patients with Graves disease. J Clin Endocrinol Metab. 2007;92(6):2182-2189.
84. Langley RW, Burch HB. Perioperative management of the thyrotoxic patient. Endocrinol Metab Clin North Am. 2003;32(2):519-534.
85. Okamura K, Sato K, FujikawaM, Bandai S, Ikenoue H, Kitazono T. Remission after potassium iodide therapy in patients with Graves hyperthyroidism exhibiting thionamide-Associated side effects. J Clin Endocrinol Metab. 2014;99(11): 3995-4002.
86. Bartalena L, Fatourechi V. Extrathyroidal manifestations of Graves disease: A 2014 update. J Endocrinol Invest. 2014;37(8):691-700.
87. Wiersinga WM. Quality of life in Graves ophthalmopathy. Best Pract Res Clin Endocrinol Metab. 2012;26(3):359-370.
88. Bahn RS. Graves ophthalmopathy.NEngl J Med. 2010;362(8):726-738.
89. Schwartz KM, Fatourechi V, Ahmed DD, Pond GR. Dermopathy of Graves disease (pretibial myxedema): long-Term outcome. J Clin Endocrinol Metab. 2002;87(2):438-446.
90. Cooper DS, Laurberg P. Hyperthyroidism in pregnancy. Lancet Diabetes Endocrinol. 2013;1(3): 238-249.
91. Korelitz JJ, McNally DL, Masters MN, Li SX, Xu Y, Rivkees SA. Prevalence of thyrotoxicosis, antithyroid medication use, and complications among pregnant women in the United States. Thyroid. 2013;23(6):758-765.
92. Sahu MT, Das V, Mittal S, Agarwal A, Sahu M. Overt and subclinical thyroid dysfunction among Indian pregnant women and its effect on maternal and fetal outcome. Arch Gynecol Obstet. 2010; 281(2):215-220.
93. Sheffield JS, Cunningham FG. Thyrotoxicosis and heart failure that complicate pregnancy. Am J Obstet Gynecol. 2004;190(1):211-217.
94. Kriplani A, Buckshee K, Bhargava VL, Takkar D, Ammini AC. Maternal and perinatal outcome in thyrotoxicosis complicating pregnancy. Eur J Obstet Gynecol Reprod Biol. 1994;54(3):159-163.
95. Hamburger JI. Diagnosis and management of Graves disease in pregnancy. Thyroid. 1992;2(3): 219-224.
96. Patil-Sisodia K,Mestman JH. Graves hyperthyroidism and pregnancy: A clinical update. Endocr Pract. 2010;16(1):118-129.
97. Krassas GE, Poppe K, Glinoer D. Thyroid function and human reproductive health. Endocr Rev. 2010;31(5):702-755.
98. De Groot L, AbalovichM, Alexander EK, et al. Management of thyroid dysfunction during pregnancy and postpartum: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(8):2543-2565.
99. Stagnaro-Green A, AbalovichM, Alexander E, et al; American Thyroid Association Taskforce on Thyroid Disease During Pregnancy and Postpartum. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid. 2011;21 (10):1081-1125.
100. US Food and Drug Administration. Medication guide: propylthiouracil tablets, USP. http://www.fda .gov/downloads/Drugs/DrugSafety/UCM208533 .pdf. Accessed November 11, 2015.
101. Yoshihara A, Noh J, Yamaguchi T, et al. Treatment of Graves disease with antithyroid drugs in the first trimester of pregnancy and the prevalence of congenital malformation. J Clin Endocrinol Metab. 2012;97(7):2396-2403.
102. Andersen SL, Olsen J,Wu CS, Laurberg P. Birth defects after early pregnancy use of antithyroid drugs: A Danish nationwide study. J Clin Endocrinol Metab. 2013;98(11):4373-4381.
103. Amino N, Tanizawa O, Mori H, et al. Aggravation of thyrotoxicosis in early pregnancy and after delivery in Graves disease. J Clin Endocrinol Metab. 1982;55(1):108-112.
104. Rotondi M, Cappelli C, Pirali B, et al. The effect of pregnancy on subsequent relapse from Graves disease after a successful course of antithyroid drug therapy. J Clin Endocrinol Metab. 2008;93(10): 3985-3988.
105. American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108(3):776-789.
106. Azizi F, Khoshniat M, Bahrainian M, Hedayati M. Thyroid function and intellectual development of infants nursed by mothers taking methimazole. J Clin Endocrinol Metab. 2000;85(9): 3233-3238.